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We demonstrate that human immunodeficiency virus HIV-1LAI envelope glycoprotein 120 (gp120LAi) specifically interacts
with several membrane ligands on lymphoid CEM or monocytic U937 cells in addition to its previously identified receptor,
CD4, and CXCR4, its coreceptor. In its native state, gp120LAI is able to elicit specific multimolecular complexes with these
membrane ligands at the surface of the cells; most of the interactions are abolished by mannan or heparin but not by dextran.
Similarly, stromal cell-derived factor (SDF)-1a interacts not only with CXCR4 expressed by CXCR41 CD41 U937, CEM, and
HOS-CD41 CXCR41 cells but also with CD4 expressed by intact U937, CEM, and HOS-CD41 CXCR41/2 cells or electroblotted
onto Immobilon. SDF-1a binding to CD41 CXCR41/2 cells, or soluble CD4 electroblotted onto Immobilon, is significantly
inhibited by sCD4, whereas truncated sCD4 lacking D3 and D4 domains had no significant effect, which indicates that SDF-1
binds to CD4 but at regions different from the HIV-gp120-binding site. Heparin and mannan also inhibit SDF-1a binding to
intact CD41 CXCR41/2 cells, and electroblotted soluble CD4. Heparitinase treatment of such cells reduced SDF-1a binding.
These data demonstrate that glycans and glycosaminoglycans are directly or indirectly involved in the interactions of HIV-1
gp120LAI and of SDF-1a with membrane ligands of CD4
1 CXCR41 cells and thus could play a role both in HIV-1 infection and
in the physiology of SDF-1a. © 1999 Academic Press
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aINTRODUCTION
CD4 is the human immunodeficiency virus type 1
HIV-1) primary receptor (Klatzmann et al., 1990), but
ther cell surface molecules are required for infection
D’Souza et al., 1996; Premack et al., 1996). HIV-1 prefer-
ntial tropism for either primary macrophages or CD41
ell lines has been accounted for by the use of CCR5 or
XCR4, respectively (D’Souza et al., 1996; Premack et al.,
996; Feng et al., 1996; Oberlin et al., 1996; Alkhatib et al.,
996; Choe et al., 1996; Deng et al., 1996; Doranz et al.,
996; Dragic et al., 1996). CCR5-using strains (R5) are
resent throughout the course of infection, whereas
XCR4-using viruses (X4) (Berger et al., 1998) often de-
elop late in disease (Scarlatti et al., 1997). RANTES
regulated on activation normal T cells expressed and
ecreted), macrophage inflammatory protein (MIP)-1b,
IP-1a, and their analogs inhibit infection by R5 strains
f cells expressing both CCR5 and CD4 (Alkhatib et al.,
996; Dragic et al., 1996., 1996; Cocchi et al., 1995; Sim-
ons et al., 1997; Ylisastigui et al., 1998; Rabehi et al.,
998; Amzazi et al., 1998), whereas SDF-1, CXCR4-spe-
1 To whom reprint requests should be addressed. Fax: 33-1-48-38-
a7-77. E-mail: liliane.gattegno@jvr.ap-hop-paris.fr.
042-6822/99 $30.00
opyright © 1999 by Academic Press
ll rights of reproduction in any form reserved.
354ific ligand, inhibits entry of X4 strains (Oberlin et al.,
996; Bleul et al., 1996).
However, HIV-1 entry is a multistep process whose
etails are yet to be elucidated. The initial binding of
p120-gp41 to CD4 is necessary but not sufficient for the
ompletion of the viral–cell fusion process. Trimolecular
omplexes among X4 strains gp120, CD4, and CXCR4
ccur on CD41 cell lines (Lapham et al., 1996; Ugolini et
l., 1997). It has also been reported (Feito et al., 1997) that
n the absence of gp120, CD4 strongly associated with
everal membrane proteins and glycoproteins. Treat-
ent with gp120 significantly increased CD4 association
ith these ligands. However, that gp120 from different
IV-1 strains induces different CD4 association patterns
uggested that gp120 directly interacts with the associ-
ting molecules.
We and others have demonstrated that HIV-1 and
IV-2 envelope glycoproteins have specific carbohydrate
inding properties for mannosyl/N-acetylglucosaminyl
esidues (Gattegno et al., 1991; Haidar et al., 1992, 1994;
bemba et al., 1996; Kage et al., 1998) and for glycos-
minoglycans such as heparin (Baba et al., 1988; Batinic
t al., 1992; Mbemba et al., 1992, 1994; Javaherian et al.,
994; Harrop et al.,1998). To expand these findings, we
imed at determining whether gp120LAI directly interacts
t the membrane of lymphoid or monocytic cells not only
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355GLYCANS, PROTEOGLYCANS, SDF-1/HIV-1 gp120 INTERACTIONSith its major previously identified receptor, CD4, and
oreceptor, CXCR4, but also with other membrane li-
ands with which it elicits multimolecular complexes and
hether glycans or glycosaminoglycans (GAGs) can
odify these interactions. We also sought to determine
hether SDF-1a directly interacts not only with its iden-
ified receptor, CXCR4, but also with other membrane
igands and whether glycans or GAGs are able to modify
hese interactions.
RESULTS
nteractions between gp120LAI and membrane ligands
ther than CD4 and CXCR4 at the membrane of CEM
nd U937 cells and multimolecular complexes
etween gp120LAI and CEM or U937 cell
embrane ligands
As expected, we found that monocytic U937 and lym-
hoid CEM cells expressed CD4 and CXCR4, as as-
essed by flow cytometry analysis (data not shown).
We examined the membrane ligands other than CD4
nd CXCR4 on U937 and CEM cells with which
125I]gp120LAI interacted and whether these interactions
ould be affected by glycans. After electroblotting mem-
rane preparations onto Immobilon strips, [125I]gp120LAI
ound to 55- and 46-kDa ligands, presumably CD4 and
XCR4, but also to several others with molecular masses
f 6–100 kDa, especially at ;40, ;34, and ;30 kDa (Fig.
a, lanes 1 and 2). Binding to all the molecules, as well
s to sCD4 migrating as a 52-kDa molecule, was abol-
shed by human anti-HIV-positive but not -negative se-
um (Fig. 1a, lanes 1–3 versus 4–6 and 7–9) and it did not
ccur with heat-denaturated gp120LAI (data not shown).
hese data demonstrate the specificity of the assay as
ell as that gp120LAI interacts with different membrane
igands, and they indeed indicate, under the conditions
sed here, involvement of the gp120 three-dimensional
tructure in the interactions.
We then determined whether gp120LAI formed multimo-
ecular complexes with these ligands of the CEM or
937 cell membrane, including CD4 and CXCR4. To this
nd, gp120LAI was incubated with the cells or their solu-
ilized membranes. The gp120LAI-bound proteins were
hen immunoprecipitated by anti-gp120LAI antibody-
oated agarose–protein A beads and analyzed after
DS–PAGE and electrotransfer. In line with the previous
ata, we found that several proteins, not only of 55 and
6 kDa but also with molecular mass ranging from 16
Da to greater than 100 kDa, especially of ;40, ;34, and
30 kDa, were retained by the beads and were able to
nteract again with native (Fig. 2, a–c) but not with heat-
enaturated gp120LAI (Fig. 2b). No bands were detected
hen radiolabeled gp120 LAI was incubated with electro-
horesed and blotted nonlabeled gp120LAI (Fig. 1c),
hich rules out the possibility that the multiple reactivi- mies detected with the gp120-precipitated material are not
result of minor contaminants in the gp120 used for
etection or for generating antisera. Similar results were
oted when gp120LAI was incubated with intact cells or
ith their membranes (Fig. 2a, lanes 1 and 2, and data
ot shown). Such multimolecular complexes were not
ormed with heat-inactivated gp120LAI (data not shown),
nd interactions of the proteins from these complexes
id not occur when using heat-denaturated [125I]rgp120LAI
Fig. 2b, lanes 4 and 5 versus 1 and 2), which demon-
trate specificity and involvement of gp120LAI three-di-
FIG. 1. Specific interactions of [125I]gp120LAI with membrane ligands
f U937 and CEM cell membranes. (a) Interactions of native
125I]gp120LAI with U937 (lanes 1, 4, and 7) or CEM (lanes 2, 5, and 8) cell
embrane ligands, or with sCD4 (lanes 3, 6, and 9), in the absence
lanes 1–3) or the presence of human anti-HIV-positive (lanes 4–6) or
negative (lanes 7–9) serum. sCD4 or membranes prepared from U937
nd CEM cells were electroblotted after SDS–PAGE and incubated with
125I]gp120LAI without or with human anti-HIV-positive or -negative se-
um. (b) Interactions of [125I]gp120LAI with U937 (lanes 1, 3, and 5) or
EM (lanes 2, 4, and 6) cell membrane ligands in the absence (lanes
and 2) or the presence of mannan (lanes 3 and 4) or dextran (lanes
and 6); membranes prepared from U937 and CEM cells were elec-
roblotted after SDS–PAGE and were incubated with [125I]gp120LAI pre-
ncubated or not with mannan or dextran, and the mixtures were then
dded to the strips. (c) Interaction of [125I]gp120LAI with electrophoresed
nd blotted nonlabeled gp120. All the results are representative of at
east three independent experiments.ensional structure.
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356 MBEMBA ET AL.Under the same conditions, mannan or heparin, but
ot dextran, abolished [125I]gp120LAI binding to most of
he membrane components or to gp120LAI–bound mem-
rane ligands electroblotted onto Immobilon (Fig. 1b,
anes 3–6 versus 1 and 2, and Fig. 2a, lanes 3–8 versus
and 2; and data not shown). Accordingly, mixing
p120LAI with heparin or mannan before incubation with
ntact cells or their membranes abolished gp120LAI bind-
ng to most components of the complexes (Fig. 2c, lanes
and 6 versus 1 and 5, lanes 3 and 7 versus 1 and 5),
hereas dextran had no effect (Fig. 2c, lanes 4 and 8
ersus 1 and 5).
Thus gp120LAI is able to bind membrane ligands
rom CEM and U937 cells, presumably other than CD4
nd CXCR4, and to form multimolecular complexes with
everal of these membrane ligands, and glycans can
irectly or indirectly interfere with most of these inter-
FIG. 2. Multimolecular complexes formation between gp120LAI and m
ncubated with U937 cell membranes (lanes 1, 3, 5, and 7) or intact U9
ysates (lanes 2, 4, 6, and 8) were then immunoprecipitated with anti-g
lectroblotted after SDS–PAGE, and incubated with [125I]gp120LAI preincu
and 6), or dextran (lanes 7 and 8). The mixtures were then added to th
and 5) cell membranes; solubilized membranes (lanes 1, 2, 4, and 5)
rotein A beads; bound components (lanes 1, 2, 4, and 5) or sCD4 (lan
lanes 1–3) or heat-treated [125I]gp120LAI (lanes 4–6). (c) gp120LAI was in
and 5) or with mannan (lanes 2 and 6), heparin (lanes 3 and 7), or d
ntibody-coated agarose–protein A beads; bound components were ele
epresentative of at least three independent experiments.ctions. cpecific interaction between SDF-1a and membrane
r soluble CD4
In the experimental conditions used here, soluble CD4
nd electroblotted membrane CD4 were repeatedly de-
ected by CD4 monoclonal antibody (mAb) Q4120, as
ands of ;50 and ;55 kDa, respectively, which is in
ccordance with Klatzmann et al. (1990); that no interac-
ion of sCD4 was detected in the presence of the isotype
ontrol demonstrates that under the presently described
onditions, specific interaction of CD4 with antibodies
an be observed (Fig. 3a, lanes 1–3 versus 6–8).
We identified CXCR4 among these U937 and CEM cell
embrane components using synthetic or recombinant
adiolabeled SDF-1a. However, we found that [125I]SDF-
a interacted with at least two membrane components:
s expected, one had a molecular mass of ;46 kDa,
ne ligands from the U937 and CEM cell membranes. (a) gp120LAI was
(lanes 2, 4, 6, and 8); solubilized membranes (lanes 1, 3, 5, and 7) or
I antibody-coated agarose–protein A beads; bound components were
without (lanes 1 and 2) or with mannan (lanes 3 and 4), heparin (lanes
s. (b) gp120LAI was incubated with U937 (lanes 1 and 4) or CEM (lanes
then immunoprecipitated with anti-gp120LAI antibody-coated agarose–
nd 6) were electroblotted after SDS–PAGE, and incubated with native
d with intact U937 (lanes 1–4) or CEM (lanes 5–8) cells without (lanes
(lanes 4 and 8). Lysates were immunoprecipitated with anti-gp120LAI
tted after SDS–PAGE and then incubated with [125I]gp120LAI. Results areembra
37 cells
p120LA
bated
e strip
were
es 3 a
cubate
extran
ctroblolose to that of CXCR4, whereas the other had a molec-
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357GLYCANS, PROTEOGLYCANS, SDF-1/HIV-1 gp120 INTERACTIONSFIG. 3. Detection of CD4 and CXCR4 in CEM and U937 cell membrane. (a) sCD4 (lanes 1 and 6), U937 (lanes 2 and 7), or CEM (lanes 3 and 8) cell
embranes or gp120LAI-bound membrane ligands from U937 (lanes 4 and 9) or CEM (lanes 5 and 10) cells were submitted to SDS–PAGE, transferred
nto Immobilon, and labeled with CD4 mAb Q4120 (lanes 1–5) or its isotype control (lanes 6–10). gp120LAI was incubated with U937 or CEM cell
embranes, and solubilized membranes were then immunoprecipitated with anti-gp120LAI antibody-coated agarose–protein A beads. Bound
omponents were blotted onto Immobilon after SDS–PAGE and labeled with the CD4 mAb (lanes 4 and 5) or the isotype control (lanes 9 and 10). (b)
nteractions of native [125I]SDF-1a (lanes 1–3 and 7–12) or heat-denaturated [125I]SDF-1a (lanes 4–6) with electroblotted membranes from U937 (lanes
, 4, 7, and 10), CEM (lanes 2, 5, 8, and 11), or HOS-CD41 CXCR41 cells (lane 3, 6, 9, and 12). Native [125I]SDF1a was incubated or not (lanes 1–3) with
nti-SDF antibodies (lanes 7–9) or the isotype control (lanes 10–12). (c) Interactions of electroblotted U937 (lanes 1 and 5), CEM (lanes 2 and 6),
OS-CD41 CXCR41 (lanes 3 and 7), or 293 cell membranes (lane 4) with anti-CXCR4 G-19 antibodies (lanes 1–4) or the isotype control (lanes 5–7).
d) Interactions of [125I]SDF-1a with gp120LAI-bound membrane ligands from U937 (lanes 1, 3, 5, and 7) and CEM cells (lanes 2, 4, 6, and 8). [
125I]SDF-1a
as incubated or not (lanes 1 and 2) with anti-CXCR4 G-19 (lanes 3 and 4) or control C-19 antibody (lanes 7 and 8) and added then to the strips. Strips
ere also incubated with peptide (P) before adding [125I]SDF-1a (lanes 5 and 6). gp120LAI was incubated with U937 or CEM cell membranes;
olubilized membranes were then immunoprecipitated with anti-gp120LAI antibody-coated agarose–protein A beads, and bound components were
lectroblotted onto Immobilon after SDS–PAGE and incubated with [125I]SDF-1a in the presence or absence of G-19 or C-19 antibodies or of peptide
. (e) Interaction of [125I]SDF-1a with intact sCD4 (lanes 1 and 6) or truncated sCD4 (lane 7) electroblotted onto Immobilon after SDS–PAGE. [125I]SDF-1a
as incubated with mannan (lane 2), heparin (lane 3), fetuin (lane 4), or sCD4 (lane 5) before addition to the strips. All data are representative of threeo five independent experiments.
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358 MBEMBA ET AL.lar mass of ;55 kDa, close to that of membrane CD4
Fig. 3b, lanes 1 and 2). Such binding was also observed
n the presence of electroblotted membrane components
rom HOS-CD41 CXCR41 cells (Fig. 3b, lane 3).
No binding was observed in the presence of heat-
enaturated [125I]SDF-1a or when [125I]SDF-1a was incu-
ated in the presence of anti-SDF-1 antibodies, whereas
125I]SDF-1a binding was not modified by the isotype
ontrol (Fig. 3b, lanes 4–6 and 7–9 versus 10–12), which
emonstrates the specificity of the assay and the role of
DF-1 three-dimensional structure. The 46-kDa band
rom U937, CEM, and HOS-CD41 CXCR41 cells was
mmunoreactive with anti-CXCR4 G-19 antibody but not
ith the isotype control (Fig. 3c, lanes 1–3 versus 5–7),
hereas electroblotted membranes from CD42 CXCR42
93 cells did not interact with G-19 antibody (Fig. 3c, lane
). These results directly demonstrates the presence of
XCR4 as a 46kDa protein in the different CXCR41 cell
embranes.
We then examined interactions of [125ISDF-1a with
p120LAI-bound membrane ligands: to this end, gp120LAI
as incubated with solubilized U937 and CEM cell mem-
ranes, and gp120LAI-bound proteins were immunopre-
ipitated by anti-gp120LAI antibody-precoated protein
–Sepharose beads and then analyzed after electroblot-
ing. Here again, CD4 mAb Q4120, but not the isotype
ontrol, interacted with electroblotted gp120LAI-bound
embrane CD4 from U937 and CEM cells (Fig. 3a, lanes
and 5) and not with the isotype control (Fig. 3a, lanes 9
nd 10), whereas [125I]SDF-1a bound to two bands of ;55
nd ;46 kDa (Fig. 3d, lanes 1 and 2). No binding was
bserved in the presence of heat-denaturated [125I]SDF-
a or when [125I]SDF-1a was incubated in the presence
f anti-SDF-1 antibodies, whereas [125I]SDF-1a binding
as not modified by the isotype control (data not shown).
inding to the 46-kDa protein was abolished by G-19
nti-CXCR4 antibody specific for the first extracellular
omain of CXCR4 (Fig. 3d, lanes 3 and 4), as well as by
eptide (P) mimicking the first extracellular domain of
XCR4 (Fig. 3d, lanes 5 and 6), whereas the isotype
ontrol had no effect (Fig. 3d, lanes 7 and 8). As ex-
ected, [125I]SDF-1a binding to the 55-kDa protein was
ot modified by G19 anti-CXCR4 antibody or by peptide P
Fig. 3d, lanes 3–6). Taken together, these data indicate
hat the 46-kDa protein corresponds to CXCR4.
Therefore, one membrane ligand of gp120 had a mo-
ecular mass of ;46 kDa, was immunoreactive with
nti-CXCR4 G-19 antibody, and specifically interacted
ith SDF-1a in a manner that was abolished by anti-
XCR4 G-19 antibody specific for the first extracellular
omain of CXCR4, as well as by the peptide P mimicking
he first extracellular domain of CXCR4. This indicates
hat at the molecular level, gp120LAI directly interacts with
XCR4 and that the first extracellular domain of CXCR4
ay be involved in SDF-1a interaction with its receptor. bWe have previously observed that gp120LAI, as well as
3Cs, specifically interacted with electroblotted sCD4
Seddiki et al., 1997; Rabehi et al., 1998). In the present
tudy, we found that [125I]SDF-1a interacted in the same
anner as [125I]gp120LAI with directly electroblotted sCD4
Fig. 3e, lanes 1 and 6). [125I]SDF-1a binding to electro-
lotted sCD4 (Fig. 3e, lanes 1 and 6) was abolished by
CD4 but not by fetuin, a glycoprotein with a molecular
ass close to that of sCD4 and used here as negative
ontrol, which indicates its specificity (Fig. 3e, lanes 4
nd 5 versus 1). That binding of [125I]SDF-1a to truncated
CD4 lacking the D3 and D4 domains was decreased
elative to intact sCD4, indicating that the latter domains
re involved in this interaction (Fig. 3e, lane 7 versus 6).
his binding was also inhibited by mannan or heparin
ut not by fetuin (Fig. 3e, lanes 2–4), suggesting that
DF-1a interaction with CD4 is carbohydrate dependent
r can be modulated by glycans.
Moreover, [125I]SDF-1a binding to intact U937 or CEM
ells, which was specifically and significantly inhibited
y 10-fold excess of unlabeled SDF-1a and by heat-
enaturation of the chemokine, was partially but signifi-
antly inhibited by sCD4 but not by truncated sCD4 nor
y fetuin, confirming the occurrence of a specific inter-
ction between SDF-1a and D3 or D4 domains of CD4, at
he surface of intact U937 or CEM cells (Table 1). These
ata also indicate that SDF-1a binds to CD4 at a region
ifferent from that involved in HIV-gp120 binding that is
ocated on the D1 domain of CD4 (Klatzmann et al., 1990).
n addition, [125I]SDF-1a binding to intact U937 or CEM
ells was also significantly inhibited by heparin and
annan but not by dextran (Table 2). Furthermore,
125I]SDF-1a binding to these cells was also significantly
nhibited by anti-CXCR4, 12G5 mAb, and G-19 antibody
ut not by the isotype controls (Table 3). These data
emonstrate that under the experimental conditions
sed here, [125I]SDF-1a binding to U937 and CEM cells
epends on CXCR4. Taken together, our data strongly
uggest that SDF-1 binding to CD41 CXCR41 U937 and
EM cells involves several different ligands. To confirm
hese data, we performed cell surface binding assays
ith SDF, by using cells that differ only with regard to
XCR4 expression. We observed that [125I]SDF-1a spe-
ifically interacted not only with HOS-CD41 CXCR41
ells but also with HOS-CD41 CXCR42 cells inasmuch as
ts binding to these cells was significantly inhibited by
eat denaturation of the chemokine as well as by its
ncubation with anti-SDF-1 antibodies but not with the
sotype control (Table 4). These bindings were also sig-
ificantly inhibited by sCD4 while truncated sCD4 or
etuin had no significant effect. Moreover, heparitinase
reatment of these cells, as well as heparin or mannan,
ignificantly inhibited [125I]SDF-1a binding, whereas dex-
ran had no significant effect (Tables 4 and 5). No specific
125 2 2inding of [ I]SDF-1a to CD4 CXCR4 293 cells was
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359GLYCANS, PROTEOGLYCANS, SDF-1/HIV-1 gp120 INTERACTIONSbserved, and enzyme treatment of these cells had no
ignificant effect (Tables 4 and 5 and data not shown).
125I]SDF-1a binding to HOS-CD41, CXCR41 cells was
lso significantly inhibited by anti-CXCR4, 12G5 mAb,
TABLE 1
Inhibition by sCD4 of SDF-1a Binding to CEM or U937 Cells
SDF-1a
binding
(cpm)
%
Inhibition
of binding
EM cells
[125I]SDF-1a (3 nM) 5600 6 510
[125I]SDF-1a 1 sCD4 (30 nM) 2920 6 280* 49 6 3
[125I]SDF-1a 1 truncated sCD4
(30 nM) 5330 6 660 5 6 5
[125I]SDF-1a 1 fetuin (30 nM) 5100 6 640 9 6 6
[125I]SDF-1a 1 unlabeled SDF-1a
(30 nM) 2350 6 400** 58 6 5
Heat-denaturated [125I]SDF-1a 630 6 200* 89 6 2
937 cells
[125I]SDF-1a (3 nM) 5700 6 470
[125I]SDF-1a 1 sCD4 (30 nM) 2690 6 520** 53 6 10
[125I]SDF-1a 1 truncated sCD4
(30 nM) 5770 6 650 0
[125I]SDF-1a 1 Fetuin (30 nM) 6580 6 960 0
[125I]SDF-1a 1 unlabeled SDF-1a
(30 nM) 1260 6 500** 78 6 10
Heat-denaturated [125I]SDF-1a 1027 6 300* 81 6 7
Note. Cells were incubated with native or heat-denaturated [125I]SDF-
a (3 nM; 50,000 cpm), in the presence or absence of unlabeled
DF-1a and washed, and cell-bound radioactivity was counted. The
ffect of soluble CD4 (sCD4), truncated sCD4, or fetuin on SDF-1a
inding to the cells was investigated as follows: [125I]SDF-1a was
ncubated with intact or truncated sCD4 or with fetuin, and the mixture
as then added to the cells. Significance of the differences with
ontrols as estimated by the paired Student’s t test: *P , .001, †P ,
.01. Results are presented as mean 6 SD of the inhibition observed
n four independent experiments performed in duplicate.
T
Effect of Heparin, Dextran and Mannan o
U937 ce
Bound radioactivity
(cpm)
125I]SDF-1a 5900 6 2120
125I]SDF-1a 1 heparin 3250 6 1200†
125I]SDF-1a 1 dextran 5100 6 2000
125I]SDF-1a 1 Mannan 3950 6 290*
125I]SDF-1a 1 unlabeled SDF-1a 1200 6 350*
eat-denaturated [125I]SDF-1a 1120 6 360*
Note. Native or heat-denaturated [125I]SDF-1a (3 nM; 50,000 cpm) wa
0 nM unlabeled SDF-1a, and the mixture was then added to the cells
n five to nine independent experiments performed in duplicate. Signifi
est: *P , .02, †P , .01.nd G-19 antibody but not by their isotype controls.
hese data suggest that SDF-1 binding to HOS-CD41
XCR41 cells also involves several different ligands,
ncluding CXCR4, CD4, and cell surface proteoglycans.
ogether, these data demonstrate at the cellular and the
olecular level that SDF-1a is able to interact not only
ith CXCR4, its previously identified receptor, but also
ith CD4, at regions different from the gp120 binding
ite, and that some steps of SDF-1a binding to CD41
ells and to CD41 CXCR41 cells are carbohydrate de-
endent or can be modulated by glycans and GAGs.
DISCUSSION
The mechanisms by which chemokine receptors par-
icipate in the process of HIV-1 entry is not entirely
nown, but different experiments suggest that gp120
nteracts with CXCR-4 (Lapham et al., 1996; Ugolini et al.,
997). The CXCR-4 chemokine receptor behaves as a
oreceptor for HIV-1 and HIV-2 strains adapted to repli-
ate in immortalized cell lines (Endres et al., 1996; Feng
t al., 1996) as well as for HIV-R4 strains replicating in
rimary cells (Simmons et al., 1998).
Similarly, the mechanisms by which chemokines, like
DF-1a, can inhibit HIV-1 entry into the cells are not
ntirely known (Amara et al., 1997). Chemokines act via
even-transmembrane domain receptors that couple to
eterotrimeric G proteins. Their antiviral activity is
hought to depend on competition for the binding of HIV
nv gp120 to chemokine receptors (Oravecz et al., 1996;
’souza et al., 1996).
Here, we demonstrate at the cellular and molecular
evels that SDF-1a specifically interacts not only with
XCR4, its previously identified receptor, but also with
embrane CD4 from CD41 CXCR41 CEM cells, U937
ells, HOS-CD41 CXCR41/2 cells, and soluble CD4.
DF-1a interaction with CD4 occurs likely with D3 and
SDF-1a Binding to U937 and CEM Cells
CEM cells
Inhibition of
binding
Bound radioactivity
(cpm)
% Inhibition of
binding
6250 6 1400
48 6 9 2830 6 890† 50 6 15
10 6 10 5600 6 1500 8 6 8
32 6 14 4410 6 100† 30 6 5
78 6 8 2400 6 1100* 58 6 20
81 6 7 650 6 220* 90 6 2
ated for 1 h at 4°C with 0–330 mg/ml heparin, dextran, or mannan or
lts are presented as mean 6 SD of the maximum inhibition observed
of the differences with controls as estimated by the paired Student’s tABLE 2
n [125I]
lls
%
s incub
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360 MBEMBA ET AL.4 domains. In one of our previous reports, we (Rabehi
t al., 1998) did not detect any interaction between sol-
ble or membrane CD4 and another chemokine, RAN-
ES, which further indicates the specificity of SDF-1a
nteraction with CD4. In addition, we currently observe
hat SDF-1 also interacts at least with two proteins from
rimary lymphocytes and monocyte-derived macro-
hages membranes (data not shown). SDF-1a binding to
CD4 was decreased by heparin and by mannan and
as not modified by fetuin, indicating that the interaction
s either carbohydrate specific or is possibly modulated
y glycans or GAGs. Accordingly, SDF-1a binding to
ntact U937, CEM, HOS-CD41 CXCR41/2 cells was also
nhibited by heparin or mannan, but not dextran, which
urther demonstrates at the cellular level that membrane
lycans and GAGs are directly or indirectly involved in
ome steps of SDF-1a binding to these cells. SDF-1a
inding to U937, CEM, and HOS-CD41 CXCR41 cells
ere also significantly inhibited by anti-CXCR4, G-19
ntibody, and 12G5 mAb, specific, respectively, for the
irst and second extracellular loops of CXCR4, which
onfirms the involvement of CXCR4. Furthermore, G-19
ntibody, as well as a peptide mimicking the first extra-
ellular loop of CXCR4, abolishes SDF-1a binding to
embrane CXCR4 electroblotted onto Immobilon. These
ata therefore indicate that the first extracellular domain
f CXCR4 may be involved, in addition to other domains,
n SDF-1a interaction with CXCR4.
We also demonstrate at the molecular level that
p120LAI specifically interacts not only with membrane
D4 and CXCR4 but also with other membrane proteins
rom lymphoid and monocytic CD41 cells; that no inter-
ctions were noted with heat-denaturated gp120LAI in-
eed indicates the role of its conformation in these
nteractions. Mannan, but not dextran, abolished gp120LAI
inding to most of the membrane components, which
T
Effect of Anti-CXCR4 Antibodies on [
U937 cells
Bound radioactivity
(cpm)
ontrol 16160 6 1920
-19 Ab 3760 6 2000‡
oat IgG 10300 6 2480
2G5 mAb 3660 6 1500†
gG2ak 9800 6 2100*
eat-denaturated SDF-1a 3155 6 600‡
Note. Native (control) or heat-denaturated [125I]SDF-1a (6 nM; 100 00
reincubated with G-19 Ab or 12G5 mAb or their isotype controls (1.3 mg
00,000 cpm) for 1 h at 4°C. Results are presented as mean 6 SD of
ignificance of the differences with controls as estimated by the pairendicates that glycans directly or indirectly interfere with aeveral of these interactions. In line with these data, we
ave previously shown that gp120 of X4 strain HIV-1LAI
pecifically interacts with N-glycans of concanavalin A-
eactive CD4-free glycopeptides prepared from U937 cell
embranes and that these glycopeptides can inhibit
IV-1LAI infection of U937 cells, as well as of CEM cells
Mbemba et al., 1996). In this line, we also recently
eported that under the same experimental conditions as
hose used here, HIV-1 gp120LAI specifically interacts
ith soluble CD4 electroblotted onto Immobilon as well
s with several membrane ligands of primary macro-
hages, and we observed carbohydrate-specific inhibi-
ions of HIV infection that depend on the cell type more
han on the viral strain, which indicate that differences in
he glycan structure of cell type-specific cofactors may
e important for HIV entry into cells (Seddiki et al., 1997).
We finally show that multimolecular complexes be-
ween gp120LAI and multiple interacting membrane mol-
cules are formed at the surface of intact CD41 lymphoid
nd monocytic cells. These complexes did not form with
eat-inactivated gp120LAI, which indicates their specific-
ty and involvement of the gp120LAI three-dimensional
tructure. Interactions of gp120LAI with most proteins of
hese complexes were abolished when gp120LAI was
reincubated with intact cells or their membranes in the
resence of heparin or mannan, whereas dextran had no
ffect. It is to be noted that SDF-1a also interacted with
membrane protein of this multimolecular complex
haracterized by the same mobility as membrane CD4
55 kDa), which is in accordance with the results de-
cribed above. That, in our experiments, one of the
p120-bound ligand had a molecular mass of ;46 kDa
nd specifically interacted with SDF in a manner that
as abolished by anti-CXCR4 polyclonal antibodies, as
ell as by a peptide mimicking the first extracellular loop
f CXCR4, indicates, at the molecular level, that gp120LAI
F-1 Binding to U937 and CEM Cells
CEM cells
ibition of
nding
Bound radioactivity
(cpm)
% Inhibition of
binding
23270 6 2100
6 26 1730 6 570‡ 92 6 3
6 24 19345 6 895 16 6 10
6 24 1980 6 415‡ 91 6 2
6 20 16815 6 4370 36 6 25
6 7 2500 6 220‡ 90 6 2
was incubated for 1 h at 4°C with the cells. Alternatively, cells were
r 1 h at 4°C; the mixture was then coincubated with [125I]SDF-1a (6 nM;
on observed in five independent experiments performed in duplicate.
ent’s t test: *P , .05; †P , .01; ‡P , .001.ABLE 3
125I]SD
% Inh
bi
70
36
72
38
81
0 cpm)
/ml) fo
inhibitilso directly interacts with CXCR4. It has been indeed
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361GLYCANS, PROTEOGLYCANS, SDF-1/HIV-1 gp120 INTERACTIONSreviously demonstrated that T-tropic HIV-1 V3 loop pep-
ides directly bind to CXCR4 and inhibit T-tropic HIV-1
nfection (Sakaida et al., 1998).
Taken together, our data indicate that gp120LAI forms
ultimolecular complexes with several membrane li-
ands at the surface of lymphoid and monocytic cells, in
ddition to CD4 and CXCR4, and that glycans and GAGs
ay directly or indirectly interfere with these interac-
ions. Moreover, we currently observe similar results with
he use of primary lymphocytes (Gattegno et al., unpub-
ished results). However, our findings do not allow us to
efine the molecular origin and structure of the glycans
nd GAGs involved in env interactions with the cellular
embranes of the CD41 CXCR41 cells. Nevertheless,
ur results may also suggest that glycans and GAGs
inding domains of env are involved directly or indirectly
n some of the steps of gp120 interactions with the cell
embrane. On another hand, these findings do not rule
TABLE 4
Effect of Soluble CD4, Glycans and GAGs on [125I]SDF-1a Binding
to HOS-CD41 CXCR41/2 Cells
Bound
radioactivity
(cpm)
% Inhibition
of binding
OS-CD41 CXCR41 cells
Control 11475 6 1200
Heat-denaturated SDF-1 1830 6 400‡ 84 6 17
Anti-SDF-1 2055 6 350† 76 6 15
Goat IgG 9195 6 300 20 6 10
sCD4 2745 6 250* 72 6 15
Truncated sCD4 5460 6 1000 46 6 36
Fetuin 11400 6 1250 0
Heparin 1635 6 380‡ 83 6 16
Mannan 3663 6 740* 65 6 23
Dextran 8400 6 1000 27 6 20
OS-CD41 CXCR42 cells
Control 7800 6 1400
Heat-denaturated SDF-1 1524 6 198* 80 6 14
Anti-SDF-1 1750 6 300* 75 6 10
Goat IgG 6000 6 220 23 6 20
sCD4 1815 6 300* 73 6 12
Truncated sCD4 6657 6 1500 14 6 14
Fetuin 6900 6 415 10 6 10
Heparin 3120 6 400* 60 6 20
Mannan 4500 6 400* 42 6 10
Dextran 7950 6 1300 0
93 cells
Control 3000 6 500
Heat-denaturated SDF-1 3450 6 330
Note. Results are mean 6 SD of the inhibition observed in four to six
ndependent experiments. *P , .05, †P , .02, ‡P , .01. Native or
eat-denaturated [125I]SDF-1a (6 nM; 100,000 cpm) was incubated with
he cells. Experimental conditions were as in Tables 1, 2, and 3. In some
xperiments, native SDF-1a was incubated for 1 h at 20°C with anti-
DF-1 antibody or the isotype control, goat IgG, both at 1.3 mg/ml.ut the occurrence of direct lateral interactions between che different membrane ligands of gp120LAI. Accordingly,
t has previously been demonstrated that CD4 and
XCR4 can be coprecipitated in the absence of gp120
Lapham et al., 1996). The roles of the presently de-
cribed interactions in HIV-1 entry into the cells and in
IV-1 infection, as well as in the effect of SDF-1a on HIV
nfection, are currently under investigation. Whether the
bility of ligands to interact with gp120 is necessary but not
ufficient for HIV coreceptor activity, which may require
ther properties, such as specific interactions with CD4,
pontaneous or in the presence of HIV envelope glycopro-
eins, is currently under investigation at our laboratory.
MATERIALS AND METHODS
ecombinant glycoprotein and peptide
Soluble recombinant gp120LAI (5 mg, .90% pure; Intra-
el, London, UK), synthetic SDF-1a (amino-acid
–67:KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCAL-
IVARLKNNNRQVCIDPKLKWQEYLEKALN; gift from F.
aleux, Institut Pasteur, Paris, France), or recombinant
DF-1a (amino acids 1–68) produced in Escherichia coli
2.5 mg, .98% pure as assessed by SDS–PAGE and
PLC; Pepro Tech EC Ltd., London, UK) was radiola-
eled in the presence of Iodobeads (Pierce Europe BA,
ud-Beijerland, the Netherlands) and of 9 MBq of Na125I
n a total volume of 100 ml of PBS. Mixtures were incu-
ated for 15 min at room temperature. The reaction was
topped with 0.9% L-tyrosine (10 ml; Sigma Chemical Co.,
t. Louis, MO). The iodinated glycoprotein or peptides
ere separated from 125I via filtration through a Sephadex
-25 (PD10) column (Pharmacia Biotech, Orsay, France).
TABLE 5
Effect of Heparitinase and of Anti-CXCR4 Antibodies
on [125I]SDF-1a Binding to HOS-CD41 CXCR41/2 Cells
Bound radioactivity
(cpm)
% Inhibition of
binding
OS-CD41 CXCR41 cells
Control 10775 6 2480
Heparitinase 4870 6 1080* 55 6 20
IgG2a, Kappa 11200 6 1190 0
12G5 mAb 2870 6 1061† 74 6 19
Goat IgG 11344 6 1190 0
G19Ab 2200 6 200† 81 6 3
OS-CD41 CXCR42 cells
Control 7460 6 110
Heparitinase 3510 6 1500† 55 6 20
93 cells
Control 3700 6 1800
Heparitinase 5130 6 920 0
Note. Results are mean 6 SD of the inhibition observed in three to
ine independent experiments. *P , .01, †P , .001. Experimental
onditions were as in Table 4. In some experiments, cells were prein-
ubated for 1 h at 37°C with heparitinase (1 mU).
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362 MBEMBA ET AL.pecific activities were ;0.4 and ;0.7 MBq/mg for
125I]gp120 and [125I]SDF-1a, respectively. In the present
tudy, similar results were obtained with synthetic or re-
ombinant SDF-1a.
ells
CD41, HIV-1LAI-susceptible monocytic U937, and lym-
hoid CEM cells (Hesselgesser et al., 1998) were cul-
ured at 37°C in RPMI 1640 (GIBCO BRL, Paisley, Scot-
and) supplemented with 10% heat-inactivated FCS
GIBCO BRL). Adherent CD42 CXCR42 293 cells, HOS-
D41 CXCR41/2 cells (National Institutes of Health AIDS
esearch and Reference Reagent Program, McKesson
ioservices, Bethesda, MD) were cultured in DMEM
GIBCO BRL) supplemented with 10% FCS, 1% penicillin-
treptomycin, and 1% L-glutamine (GIBCO BRL). In the
ase of HOS-CD41 CXCR41 cells, medium was also
upplemented with 1% puromycin (GIBCO BRL).
mmunofluorescence analysis of cells
Indirect immunofluorescence assay. Cells (5 3 105)
ere incubated for 30 min at 20°C in 100 ml of PBS,
.05% BSA, and 0.05% sodium azide (PBS-BSA-A) with or
ithout anti-CXCR4 mAb 12G5 (2.5 mg; PharMingen, San
iego, CA) or its isotype IgG2a control (Sigma). After
ashing, cells were incubated for 30 min at 20°C in 100
l of FITC-labeled anti-mouse IgG goat antibodies
Coulter Electronics, France) diluted 1:20 in buffer. After
hree washes at 20°C, cells were fixed in 1% paraformal-
ehyde (Sigma) in PBS.
Direct immunofluorescence assay. Cells were incu-
ated for 30 min at 20°C in PBS-BSA-A with FITC-CD4 (1
g; clone 13B.8.2) or its isotype control (1 mg; IgG1-FITC;
oth from Immunotech, Marseille, France). Flow cytom-
try analysis was performed with an FACScan (Becton
ickinson, Mountain View, CA).
nteractions of gp120LAI with cell membrane ligands
Cells (2.5 3 108) were washed three times in Ca21-free
BS, pH 7.4, and incubated for 30 min at 4°C in 25 ml of
ysis buffer (0.01 M Tris–HCl, pH 7.5, 1.5 mM MgCl2, 1 mM
MSF; all from Sigma). Cell lysates were depleted from
uclear constituents by centrifugation (1000g, 30 min,
°C). Membranes were obtained by centrifugation for 90
in at 4°C, at 100,000g; the cell pellet was suspended in
0 ml of 0.05 M Tris–HCl, pH 6.8, and 2 mM EDTA, and
entrifuged at 40,000g for 30 min at 4°C. Membranes
ere suspended in 100–500 ml of PBS. Protein concen-
ration was determined with the Bradford reagent (Bio-
ad, Paris, France). Aliquots were analyzed by SDS–
AGE (4–20% or 12% polyacrylamide) under reducing
onditions, followed by Coomassie or silver staining.
ontrol electrophoresis of soluble CD4 (sCD4; gift from
. Klatzmann, CERVI, Hoˆpital Pitie´ Salpeˆtrie`re, Paris, brance) or truncated sCD4 (a gift from M. Hofnung, In-
titut Pasteur, France, prepared as described by Szmel-
man et al., 1990, and lacking D3 and D4 domains and
till presenting D1 and D2 domains; it was verified that
his construction specifically binds gp120LAI) were per-
ormed under the same conditions.
Also, membrane preparations, sCD4 or truncated
CD4, submitted to SDS–PAGE (4–20% or 12%) under
educing conditions were electroblotted onto Immobilon
trips (Millipore, Paris, France). Strips were saturated for
–18 h at 37°C with PBS and 5% BSA (Sigma) (PBS-BSA).
xcess BSA was washed out with PBS, 0.5% BSA, and
.2% Tween 20 (Sigma), and strips were incubated for
–18 h at 20°C or 37°C with either 1–2 3 106 cpm
125I]rgp120LAI (10
29 M) or [125I]SDF-1a (8 3 1029 M). After
ix washes with the buffer, strips were exposed at
20°C for 18–72 h. Alternatively, [125I]rgp120LAI was pre-
ncubated for 45 min at 37°C with 5 mg/ml mannan or
extran (all from Sigma) before addition to the strips.
CD4 (2 ml, 0.75 mg) was used as positive control. In
ome experiments, [125I]gp120LAI was heat-inactivated for
0 min at 100°C in the presence of 1% SDS and 5%
-mercaptoethanol (Sigma). Also, [125I]gp120LAI was incu-
ated for 3–18 h at 20°C or 37°C with a human HIV-1-
ositive or -negative serum or nonimmune rabbit serum
all at 1:50); the mixture was then added to the strips for
–18 h at 37°C. In parallel, strips were incubated with
D4 mAb Q4120 or its isotype control (both at 0.2 mg/ml;
igma) and stained with horseradish peroxidase-labeled
orse anti-mouse antibody followed by ECL photolumi-
escence detection (Amersham, Great Chalfont, UK).
Alternatively, [125I]SDF-1a was incubated for 45 min at
7°C with 5 mg/ml mannan, heparin, dextran, or fetuin
all from Sigma) or sCD4 (2 mg/ml) before addition to the
trips. To verify specificity of the assay, [125I]SDF-1a was
ncubated in parallel for 2 h at 37°C with 2 mg/10 ml of
-19 antibody (a goat polyclonal antibody raised against
peptide P, GYQKKLRSMTDKYRLHLSV, mimicking ac-
ording to Brelot et al., 1997, the first extracellular domain
f CXCR-4) or C-19 antibody (affinity-purified goat poly-
lonal antibody, used here as an isotype control) (both
rom Pepro Tech EC Ltd.). The mixture was then added to
he strips as described above. Strips were also preincu-
ated with 2 mg/10 ml of the peptide P before adding
125I]SDF-1a. Alternatively, strips were also incubated
ith heat-treated (10 min at 100°C) [125I]SDF-1 or with a
ixture of SDF-1 and anti-SDF-1 goat polyclonal antibod-
es or its isotype control (both at 1.3 mg/ml; R and D
ystems Europe, Oxford, UK). In parallel, strips were
ncubated with G-19 anti-CXCR4 antibody or its isotype
ontrol (both at 0.2 mg/ml) and stained with horseradish
eroxidase-labeled rabbit anti-mouse antibody followed
y ECL detection. As controls, native or heat-treated
125I]SDF-1 was also incubated with electroblotted mem-
1 1ranes prepared from HOS-CD4 , CXCR4 cells and
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363GLYCANS, PROTEOGLYCANS, SDF-1/HIV-1 gp120 INTERACTIONSrom CD42, CXCR42 293 cells in the presence or ab-
ence of anti-SDF-1 antibodies or the isotype control.
etection of multimolecular complexes between
p120LAI and cell membrane ligands
Washed cells (108) in 200 ml of PBS were incubated for
h at 37°C with native or heat-treated gp120LAI (2 mg) in
he presence or the absence of mannan, heparin, or
extran (all at 1 mg/ml). Cells were then washed three
imes by centrifugation (700g, 10 min, 4°C) and lysed by
ncubation for 30 min in ice in 10 mM Tris–HCl buffer, pH
.2, 150 mM NaCl, and 1% v/v Brij 97 (Sigma), supple-
ented with protease inhibitors (10 mM PMSF, 25 mM
henanthrolin, 5 mM iodoacetamide, 100 mg/ml aproti-
in; all from Sigma). Cell lysates were depleted from
uclear constituents by centrifugation (1000g, 30 min,
°C). Lysates were immunoprecipitated by incubation for
8 h at 4°C with 100 ml of agarose–protein A beads (EY
aboratories, San Mateo, CA) precoated with rabbit anti-
p120LAI polyclonal antibodies (2.5 mg; Neosystem,
trasbourg, France). Binding of antibodies to beads was
erformed for 2 h at 20°C, and beads were exhaustively
ashed in buffer. Beads were then washed three times
ith buffer to remove unbound components, suspended
n 100 ml of 23 Laemmli’s buffer, heated for 10 min at
00°C to release bound components, and subsequently
nalyzed by SDS–PAGE (12%) followed or not followed by
lectrotransfer onto Immobilon and incubation with in-
act or heat-treated [125I]gp120LAI, in the presence or ab-
ence of rabbit polyclonal anti-gp120 antibodies, as de-
cribed above, or in the presence or absence of mannan,
eparin, or dextran (5 mg/ml). As negative control,
p120LAI (2 mg) was electrophoresed and blotted, as
escribed above, and the strip was incubated with io-
ide-labeled gp120LAI. In parallel, strips were incubated
ith CD4 mAb Q4120 or its isotype control (both at 0.2
g/ml) or with [125I]SDF-1a (106 cpm) as described above,
n the presence or absence of sCD4, truncated CD4,
-19 anti-CXCR4 antibodies, its isotype control, peptide
, mannan, heparin, dextran, or fetuin. Alternatively, cell
embranes (100 ml, 500 mg/ml), were solubilized as
escribed above, incubated for 3 h at 37°C with 2 mg
p120LAI, and immunoprecipitated with rabbit anti-
p120LAI polyclonal antibody-coated agarose–protein A
eads (2.5 mg). Immunoprecipitates were analyzed as
escribed above. In parallel, strips were also incubated
ith CD4 mAb Q4120 or its isotype control (both at 0.2
g/ml) or with [125I]SDF-1a (106 cpm) as described.
DF-1a binding to cells
Nonadherent U937 and CEM cells (0.5–1 3 106) or
dherent CD42 CXCR42 293 cells, HOS-CD41 CXCR41/2
ells (106) in 150–250 ml of RPMI 1640 or DMEM, 0.05%
SA (RPMI-BSA or DMEM-BSA) were incubated for 1–2 h Bt 4°C with 50–100 ml of native or heat-treated (10 min at
00°C) [125I]SDF-1a (0.5–1 3 105 cpm; 3–6 3 1029 M) in
he presence or absence of 10-fold excess of unlabeled
DF-1a. After two washes (700g, 10 min,; 4°C), cell-
ound radioactivity was measured with a gamma
ounter (LKB, Paris, France). The effect of sCD4, trun-
ated sCD4, or bovine fetuin (all at 30 nM) on SDF-1a
inding to cells was examined in conditions that did not
lter cell viability, as follows: [125I]SDF-1a in RPMI-BSA or
MEM-BSA was incubated for 60 min at 37°C with sCD4
r truncated sCD4, or with fetuin, and the mixture was
dded to the cells and incubated as described above. In
ome experiments, the effects of heparin, mannan, or
extran on SDF-1a binding to the cells were tested at
oncentrations of up to 330 mg/ml, which did not alter
ell viability. Alternatively, 106 cells were incubated for
h at 37°C in 50 ml of PBS, 0.05% BSA, and 1 mU
eparitinase (heparitin sulfate eliminase, EC.4.2.2.8; from
igma), supplemented with protease inhibitors (10 mM
MSF, 25 mM phenanthrolin, 5 mM iodoacetamide, 100
g/ml aprotinin). After washing, cells were incubated
ith [125I]SDF-1. The enzyme was not toxic for the cells,
s assessed by trypan blue exclusion. In other experi-
ents, [125I]SDF-1a was preincubated for 1 h at 20°C
ith goat polyclonal anti-SDF-1 (1.3 mg/ml; R & D) or its
sotype control (R & D), and the mix was then incubated
ith the cells as described. Alternatively, cells were
reincubated for 1 h at 4°C with anti-CXCR4, G-19 anti-
ody, or 12G5 mAb (both at 1.3 mg/ml), or with their
sotype controls, goat IgG (R & D) or IgG2ak (Sigma).
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